|
SFRS15 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.5053964699332E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.34389999631546E-08 |
| Normal-vs-Stage2 |
2.14530000000046E-05 |
| Normal-vs-Stage3 |
1.97269978130521E-10 |
| Normal-vs-Stage4 |
7.54750000275806E-08 |
| Stage1-vs-Stage2 |
7.116000E-01 |
| Stage1-vs-Stage3 |
9.837500E-03 |
| Stage1-vs-Stage4 |
2.125800E-01 |
| Stage2-vs-Stage3 |
1.684220E-01 |
| Stage2-vs-Stage4 |
4.863400E-01 |
| Stage3-vs-Stage4 |
4.771800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.21219997875721E-09 |
| Normal-vs-AfricanAmerican |
1.682880E-03 |
| Normal-vs-Asian |
1.044630E-04 |
| Caucasian-vs-AfricanAmerican |
7.231600E-01 |
| Caucasian-vs-Asian |
3.821200E-01 |
| AfricanAmerican-vs-Asian |
7.907000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.05600003478202E-09 |
| Normal-vs-Female |
5.60040014363494E-10 |
| Male-vs-Female |
7.709000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.6600999947799E-08 |
| Normal-vs-Age(41-60Yrs) |
1.64929999657559E-08 |
| Normal-vs-Age(61-80Yrs) |
2.24239959933925E-10 |
| Normal-vs-Age(81-100Yrs) |
1.481790E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.571200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.930000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.561600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.999000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.666800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.513200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.884600E-03 |
| Classical-VS-Follicular |
2.987700E-04 |
| Classical-VS-Other |
4.208800E-01 |
| Classical-VS-Normal |
1.15760000030107E-07 |
| Tall-VS-Follicular |
8.061000E-01 |
| Tall-VS-Other |
5.658800E-01 |
| Tall-VS-Normal |
1.57669999945043E-07 |
| Follicular-VS-Other |
7.047800E-01 |
| Follicular-VS-Normal |
8.79689987520749E-10 |
| Other-VS-Normal |
1.497830E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.99829996994083E-09 |
| Normal-vs-N1 |
1.40079999999543E-06 |
| N0-vs-N1 |
9.366400E-01 |
|
|
